In Vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin

Current Cancer Drug Targets

Volumn 10, Issue 3, 2010, Pages 279-286

  Gonzalez A ^a   Alvarez Garcia V ^a   Martinez Campa C ^a   Mediavilla, M D ^a   Alonso Gonzalez C ^a   Sanchez Barcelo E J ^a   Cos, S ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Breast cancer; DMBA; Melatonin; Pineal; Sulfatase

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; ESTROGEN SULFATASE; ESTRONE SULFATE; MELATONIN; MESSENGER RNA; MICROSOME ENZYME; SULFATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST ADENOCARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FEMALE; NONHUMAN; OVARIECTOMY; PROTEIN EXPRESSION; RAT; TUMOR GROWTH; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTRONE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SULFATASES; TIME FACTORS; TUMOR BURDEN; UTERUS;

EID: 77952847081     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791190201     Document Type: Article

References (40)

1. Blask, D. E.; Sauer, L. A.; Dauchy, R. T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002, 2, 113-132.
2. Cos, S.; Sánchez-Barceló, E. J. Melatonin and mammary pathological growth. Front. Neuroendocrinol. 2000, 21, 133-170.
3. Cos, S.; Sánchez-Barceló, E. J. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol. Histopathol. 2000, 15, 637-647.
4. González, A.; Martínez-Campa, C.; Mediavilla, M. D.; Alonso-González, C.; Sánchez-Barceló, E. J.; Cos, S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expresión in rat glioma cells. Br. J. Cancer 2007, 97, 755-760.
5. Cos, S.; García-Bolado, A.; Sánchez-Barceló, E. J. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). Melanoma Res. 2001, 11, 197-201.
6. Sánchez-Barceló, E. J.; Cos, S.; Fernández, R.; Mediavilla, M. D. Melatonin and mammary cancer: a short review. Endocr. Relat. Cancer 2003, 10, 153-159.
7. Cos, S.; González, A.; Martínez-Campa, C.; Mediavilla, M. D.; Alonso-González, C.; Sánchez-Barceló, E. J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect. Prev. 2006, 30, 118-128.
8. Del Rio, B.; García-Pedrero, J. M.; Martínez-Campa, C.; Zuazua, P.; Lazo, P. S.; Ramos, S. Melatonin: an endogenous specific inhibitor of estrogen receptor via calmodulin. J. Biol. Chem. 2004, 279, 38294-38302.
9. Cos, S.; Martínez-Campa, C.; Mediavilla, M. D.; Sánchez-Barceló, E. J. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J. Pineal. Res. 2005, 38, 136-142.
10. Cos, S.; González, A.; Martínez-Campa, C.; Mediavilla, M. D.; Alonso-González, C.; Sánchez-Barceló, E. J. Melatonin as a selective estrogen enzyme modulator. Curr. Cancer Drug Targets 2008, 8, 691-702.
11. González, A.; Martínez-Campa, C.; Mediavilla, M. D.; Alonso-González, C.; Sánchez-Mateos, S.; Hill, S. M.; Sanchez-Barceló, E. J.; Cos, S. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol. Rep. 2007, 17, 947-955.
12. Cos, S.; González, A.; Güezmes, A.; Mediavilla, M. D.; Martínez-Campa, C.; Alonso-González, C.; Sánchez-Barceló, E. J. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 2006, 118, 274-278.
13. Simpson, E. R. Role of aromatase in sex steroid action. J Mol Endocrinol 2000, 25, 149-156.
14. Landeghem, A. A.; Poortman, J.; Nabuurs, M.; Thijssen, J. H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 1985, 45, 2900-2906.
15. Yue, W.; Wang, J. P.; Hamilton, C. J.; Demers, L. M.; Santen, R. J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998, 58, 927-932.
16. Suzuki, T.; Miki, Y.; Nakamura, Y.; Moriya, T.; Ito, K.; Ohuchi, N.; Sasano, H. Sex steroid-producing enzymes in human breast cancer. Endocr. Relat. Cancer 2005, 12, 701-720.
17. Utsumi, T.; Yoshimura, N.; Takeuchi, S.; Maruta, M.; Maeda, K.; Harada, N. Elevated steroid sulfatase expression in breast cancer. J. Steroid Biochem. Mol. Biol. 2000, 73, 141-145.
18. Pasqualini, J. R. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 2004, 1654, 123-143.
19. González, A.; Cos, S.; Martínez-Campa, C.; Alonso-González, C.; Sánchez-Mateos, S.; Mediavilla, M. D.; Sánchez-Barceló, E. J. Selective estrogen enzime modulator (SEEM) actions of melatonin in human breast cancer cells. J. Pineal Res. 2008, 45, 86-92.
20. Ram, P. T.; Kiefer, T.; Silverman, M.; Song, Y.; Brown, G. M.; Hill, S. M. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Mol. Cell Endocrinol. 1998, 141, 53-64.
21. Yuan, L.; Collins, A. R.; Dai, J.; Dubocovich, M. L.; Hill, S. M. MT1 melatonin receptor overexpression enhances the growth suppressive effects of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002, 192, 147-156.
22. Masamura, S.; Santner, S. J.; Santen, R. J. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J. Steroid Biochem. Mol. Biol. 1996, 58, 425-429.
23. Rose, D. P.; Noonan, J. J. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea. Cancer Res. 1982, 42, 35-38.
24. Duncan, L.; Purohit, A.; Howarth, N. M.; Potter, B. U.; Reed, M. J. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res. 1993, 53, 298-303.
25. Howell, A.; Clarke, R. B.; Anderson, E. Oestrogens, Beatson and endocrine therapy. Endocr. Relat. Cancer 1997, 4, 371-380.
26. Russo, I. H.; Russo, J. Role of hormones in mammary cancer initiation and progression. J. Mamm. Gland Biol. Neoplasia 1998, 3, 49-61.
27. Pasqualini, J. R.; Chetrite, G. S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 2005, 93, 221-236.
28. Purohit, A.; Newman, S. P.; Reed, M. J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002, 4, 65-69.
29. Barker, S. Anti-estrogens in the treatment of breast cancer: current status and future directions. Curr. Opin. Investig. Drugs 2003, 4, 652-657.
30. Cos, S.; Garijo, F.; Corral, J.; Mediavilla, M. D.; Sánchez-Barceló, E. J. Histopathologic features of DMBA-induced mammary tumors in blind-underfed, blind-anosmic, and blind cold-exposed rats: Influence of the pineal gland. J. Pineal Res. 1989, 6, 221-231.
31. Bradley, C. J.; Kledzik, G. S.; Meites, J. Prolactin and estrogen dependency of rat mammary cancers at early and late stages of development. Cancer Res. 1976, 36, 319-324.
32. Ma, D. F.; Katoh, R.; Zhou, H.; Wang, P. Y. Promoting effects of milk on the development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in rats. Acta Histochem. Cytochem. 2007, 40, 61-67.
33. She, M.; Deng, X.; Guo, Z.; Laudon, M.; Hu, Z.; Liao, D.; Hu, X.; Luo, Y.; Shen, Q.; Su, Z.; Yin, W. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol. Res. 2009, 59, 248-253.
34. Evans, T. R.; Rowlands, M. G.; Luqmani, Y. A.; Chander, S. K.; Coombes, R. C. Detection of breast cancer-associated estrone sulfatase in breast cancer biopsies and cell lines using polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 1993, 46, 195-201.
35. Fraschini, F.; Demartini, G.; Esposti, D.; Scaglione, F. Melatonin involvement in immunity and cancer. Biol. Signals Recept. 1998, 7, 61-72.
36. Sánchez-Barceló, E. J.; Cos, S.; Mediavilla, M. D.; Martínez-Campa, C.; González, A.; Alonso-González, C. Melatonin-estrogen interactions in breast cancer. J. Pineal. Res. 2005, 38, 217-222.
37. Molis, T. M.; Spriggs, L. L.; Hill, S. M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol. Endocrinol. 1994, 8, 1681-1690.
38. Hill, S. M.; Spriggs, L. L.; Simon, M. A.; Muraoka, H.; Blask, D. E. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 1992, 64, 249-256.
39. Cos, S.; Mediavilla, M. D.; Martínez-Campa, C.; González, A.; Alonso-González, C.; Sánchez-Barceló, E. J. Exposure to light at night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett. 2006, 235, 266-271.
40. Blask, D. E.; Brainard, G. C.; Dauchy, R. T.; Hanifin, J. P.; Davidson, L. K.; Krause, J. A.; Sauer, L. A.; Rivera-Bermudez, M. A.; Dubocovich, M. L.; Jasser, S. A.; Lynch, D. T.; Rollag, M. D.; Zalatan, F. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005, 65, 11174-11184.